Loading…
Virus-Like-Vaccines against HIV
Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP...
Saved in:
Published in: | Vaccines (Basel) 2018-02, Vol.6 (1), p.10 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53 |
---|---|
cites | cdi_FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53 |
container_end_page | |
container_issue | 1 |
container_start_page | 10 |
container_title | Vaccines (Basel) |
container_volume | 6 |
creator | Andersson, Anne-Marie C Schwerdtfeger, Melanie Holst, Peter J |
description | Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses. Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV. Such vaccines are immunologically perceived as viruses, as they infect cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors and VLPs cannot propagate an infection. The inherent safety of such a platform, despite robust particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and immunogenicity. Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors and we have developed the concept into a single-reading adenovirus-based technology capable of eliciting robust CD8⁺ and CD4⁺ T cells responses and trimer binding antibody responses. Such vaccines offer the potential to display the naturally produced immunogen directly and induce an integrated humoral and cellular immune response. |
doi_str_mv | 10.3390/vaccines6010010 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2c2bce0fb9db468485576d4d5e416d33</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_2c2bce0fb9db468485576d4d5e416d33</doaj_id><sourcerecordid>2026484134</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53</originalsourceid><addsrcrecordid>eNpdkUtrGzEURkVJaYKbdXetIZtuppZ09dwEQkhig6Gb1nQnJI3GkTOecaWZQP59ldgNcYRAQjr3cKUPoS8E_wDQePZovY9dyAITXOYHdEaxFBVo-HPyZn-KznPe4DI0ASXkJ3RKNQPNpDhD31YxjblaxodQrQ6-qV3b2OVhOl-sPqOPjW1zOD-sE_T79ubX9bxa_rxbXF8tK8-UHCpnGfcEtNW1sAQ8BaUkEOy5ck5xoKThguCgRAHA-kZR7rBTpY1GSMthghZ7b93bjdmluLXpyfQ2mpeDPq2NTUP0bTDUU-cDbpyuHROKKc6lqFnNAyOiBiiuy71rN7ptqH3ohmTbI-nxTRfvzbp_NFxJJjgpgu8HQer_jiEPZhuzD21ru9CP2VCMKSVKC1nQi3foph9TV76qUFQwxQiwQs32lE99zik0r80QbJ6zNO-yLBVf377hlf-fHPwDPE-Y1A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2026484134</pqid></control><display><type>article</type><title>Virus-Like-Vaccines against HIV</title><source>Access via ProQuest (Open Access)</source><source>IngentaConnect Journals</source><source>PubMed Central</source><creator>Andersson, Anne-Marie C ; Schwerdtfeger, Melanie ; Holst, Peter J</creator><creatorcontrib>Andersson, Anne-Marie C ; Schwerdtfeger, Melanie ; Holst, Peter J</creatorcontrib><description>Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses. Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV. Such vaccines are immunologically perceived as viruses, as they infect cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors and VLPs cannot propagate an infection. The inherent safety of such a platform, despite robust particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and immunogenicity. Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors and we have developed the concept into a single-reading adenovirus-based technology capable of eliciting robust CD8⁺ and CD4⁺ T cells responses and trimer binding antibody responses. Such vaccines offer the potential to display the naturally produced immunogen directly and induce an integrated humoral and cellular immune response.</description><identifier>ISSN: 2076-393X</identifier><identifier>EISSN: 2076-393X</identifier><identifier>DOI: 10.3390/vaccines6010010</identifier><identifier>PMID: 29439476</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>antibodies ; CD4 antigen ; CD8 antigen ; Coding ; Cytotoxicity ; Drug delivery systems ; Expression vectors ; Glycoproteins ; HIV ; Human immunodeficiency virus ; Immune response ; Immune response (cell-mediated) ; Immune response (humoral) ; Immune system ; Immunogenicity ; Lymphocytes ; Lymphocytes T ; Particle production ; Replication ; Review ; Safety ; T cells ; Vaccines ; Vaccinia ; virus vectors ; virus-like-particles ; virus-like-vaccines ; Viruses</subject><ispartof>Vaccines (Basel), 2018-02, Vol.6 (1), p.10</ispartof><rights>Copyright MDPI AG 2018</rights><rights>2018 by the authors. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53</citedby><cites>FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2026484134/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2026484134?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29439476$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andersson, Anne-Marie C</creatorcontrib><creatorcontrib>Schwerdtfeger, Melanie</creatorcontrib><creatorcontrib>Holst, Peter J</creatorcontrib><title>Virus-Like-Vaccines against HIV</title><title>Vaccines (Basel)</title><addtitle>Vaccines (Basel)</addtitle><description>Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses. Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV. Such vaccines are immunologically perceived as viruses, as they infect cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors and VLPs cannot propagate an infection. The inherent safety of such a platform, despite robust particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and immunogenicity. Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors and we have developed the concept into a single-reading adenovirus-based technology capable of eliciting robust CD8⁺ and CD4⁺ T cells responses and trimer binding antibody responses. Such vaccines offer the potential to display the naturally produced immunogen directly and induce an integrated humoral and cellular immune response.</description><subject>antibodies</subject><subject>CD4 antigen</subject><subject>CD8 antigen</subject><subject>Coding</subject><subject>Cytotoxicity</subject><subject>Drug delivery systems</subject><subject>Expression vectors</subject><subject>Glycoproteins</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Immune response</subject><subject>Immune response (cell-mediated)</subject><subject>Immune response (humoral)</subject><subject>Immune system</subject><subject>Immunogenicity</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Particle production</subject><subject>Replication</subject><subject>Review</subject><subject>Safety</subject><subject>T cells</subject><subject>Vaccines</subject><subject>Vaccinia</subject><subject>virus vectors</subject><subject>virus-like-particles</subject><subject>virus-like-vaccines</subject><subject>Viruses</subject><issn>2076-393X</issn><issn>2076-393X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkUtrGzEURkVJaYKbdXetIZtuppZ09dwEQkhig6Gb1nQnJI3GkTOecaWZQP59ldgNcYRAQjr3cKUPoS8E_wDQePZovY9dyAITXOYHdEaxFBVo-HPyZn-KznPe4DI0ASXkJ3RKNQPNpDhD31YxjblaxodQrQ6-qV3b2OVhOl-sPqOPjW1zOD-sE_T79ubX9bxa_rxbXF8tK8-UHCpnGfcEtNW1sAQ8BaUkEOy5ck5xoKThguCgRAHA-kZR7rBTpY1GSMthghZ7b93bjdmluLXpyfQ2mpeDPq2NTUP0bTDUU-cDbpyuHROKKc6lqFnNAyOiBiiuy71rN7ptqH3ohmTbI-nxTRfvzbp_NFxJJjgpgu8HQer_jiEPZhuzD21ru9CP2VCMKSVKC1nQi3foph9TV76qUFQwxQiwQs32lE99zik0r80QbJ6zNO-yLBVf377hlf-fHPwDPE-Y1A</recordid><startdate>20180211</startdate><enddate>20180211</enddate><creator>Andersson, Anne-Marie C</creator><creator>Schwerdtfeger, Melanie</creator><creator>Holst, Peter J</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180211</creationdate><title>Virus-Like-Vaccines against HIV</title><author>Andersson, Anne-Marie C ; Schwerdtfeger, Melanie ; Holst, Peter J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>antibodies</topic><topic>CD4 antigen</topic><topic>CD8 antigen</topic><topic>Coding</topic><topic>Cytotoxicity</topic><topic>Drug delivery systems</topic><topic>Expression vectors</topic><topic>Glycoproteins</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Immune response</topic><topic>Immune response (cell-mediated)</topic><topic>Immune response (humoral)</topic><topic>Immune system</topic><topic>Immunogenicity</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Particle production</topic><topic>Replication</topic><topic>Review</topic><topic>Safety</topic><topic>T cells</topic><topic>Vaccines</topic><topic>Vaccinia</topic><topic>virus vectors</topic><topic>virus-like-particles</topic><topic>virus-like-vaccines</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andersson, Anne-Marie C</creatorcontrib><creatorcontrib>Schwerdtfeger, Melanie</creatorcontrib><creatorcontrib>Holst, Peter J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Vaccines (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andersson, Anne-Marie C</au><au>Schwerdtfeger, Melanie</au><au>Holst, Peter J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Virus-Like-Vaccines against HIV</atitle><jtitle>Vaccines (Basel)</jtitle><addtitle>Vaccines (Basel)</addtitle><date>2018-02-11</date><risdate>2018</risdate><volume>6</volume><issue>1</issue><spage>10</spage><pages>10-</pages><issn>2076-393X</issn><eissn>2076-393X</eissn><abstract>Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses. Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV. Such vaccines are immunologically perceived as viruses, as they infect cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors and VLPs cannot propagate an infection. The inherent safety of such a platform, despite robust particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and immunogenicity. Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors and we have developed the concept into a single-reading adenovirus-based technology capable of eliciting robust CD8⁺ and CD4⁺ T cells responses and trimer binding antibody responses. Such vaccines offer the potential to display the naturally produced immunogen directly and induce an integrated humoral and cellular immune response.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>29439476</pmid><doi>10.3390/vaccines6010010</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2076-393X |
ispartof | Vaccines (Basel), 2018-02, Vol.6 (1), p.10 |
issn | 2076-393X 2076-393X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_2c2bce0fb9db468485576d4d5e416d33 |
source | Access via ProQuest (Open Access); IngentaConnect Journals; PubMed Central |
subjects | antibodies CD4 antigen CD8 antigen Coding Cytotoxicity Drug delivery systems Expression vectors Glycoproteins HIV Human immunodeficiency virus Immune response Immune response (cell-mediated) Immune response (humoral) Immune system Immunogenicity Lymphocytes Lymphocytes T Particle production Replication Review Safety T cells Vaccines Vaccinia virus vectors virus-like-particles virus-like-vaccines Viruses |
title | Virus-Like-Vaccines against HIV |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T09%3A20%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Virus-Like-Vaccines%20against%20HIV&rft.jtitle=Vaccines%20(Basel)&rft.au=Andersson,%20Anne-Marie%20C&rft.date=2018-02-11&rft.volume=6&rft.issue=1&rft.spage=10&rft.pages=10-&rft.issn=2076-393X&rft.eissn=2076-393X&rft_id=info:doi/10.3390/vaccines6010010&rft_dat=%3Cproquest_doaj_%3E2026484134%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c487t-ba45c139a9d6a13c23887310c58bb85321f5610e869d63acf825b0b8439f67a53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2026484134&rft_id=info:pmid/29439476&rfr_iscdi=true |